SEC Comment Letter 0000000000-23-005277 to Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Date: May 17, 2023 · CIK: 0001792581 · Accession: 0000000000-23-005277
AI Filing Summary & Sentiment
File numbers found in text: 333-271950
Letter
United States securities and exchange commission logo May 17, 2023 Pietro Bersani, CPA. Chief Executive Officer Kiromic Biopharma, Inc. 7707 Fannin, Suite 140 Houston, TX 77054 Re:Kiromic Biopharma, Inc. Registration Statement on Form S-1 Filed May 15, 2023 File No. 333-271950 Dear Pietro Bersani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Greg Carney, Esq.
Show Raw Text
United States securities and exchange commission logo
May 17, 2023
Pietro Bersani, CPA.
Chief Executive Officer
Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
Re:Kiromic Biopharma, Inc.
Registration Statement on Form S-1
Filed May 15, 2023
File No. 333-271950
Dear Pietro Bersani:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Greg Carney, Esq.